EUVIMEDEUVIMED entdecken
Crossref

In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 78-79

DOI: 10.58347/tml.2026.1754e ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets (Viagra, and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.

Schlagwörter

Stichwörter der Autor:innen

CialisEroxonStendraViagraVybriqueadverse effectsalprostadilavanafildosagedrug interactionsefficacyerectile dysfunctionsafetysildenafiltadalafil

Zitieren

APA

(2026). In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction. The Medical Letter on Drugs and Therapeutics, 68(1754), 78-79. https://doi.org/10.58347/tml.2026.1754e

Vancouver

In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):78-79. doi:10.58347/tml.2026.1754e

BibTeX
@article{euvimed2026,
  title = {In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {78--79},
  doi = {10.58347/tml.2026.1754e}
}
Kostenlos starten →